aTyr Pharma Announces Publication of Results from the Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis in The Lancet Respiratory Medicine
aTyr Pharma Announces Publication Demonstrating Anti-Fibrotic Effects of ATYR0101 in the Journal of Biological Chemistry
aTyr Pharma Provides Update on Timing of Regulatory Response for Planned Phase 3 Study of Efzofitimod in Pulmonary Sarcoidosis
aTyr Pharma to Present Subgroup Analysis of Phase 3 EFZO-FIT Study of Efzofitimod in Pulmonary Sarcoidosis at WASOG 2026
aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
Premier American Uranium Completes US$5 Million Strategic Equity Investment by DISA Uranium; IsoEnergy Increases its Strategic Holding
